公开(公告)号：US20140057319A1

公开(公告)日：2014-02-27

申请号：US13974655

申请日：2013-08-23

Applicant: Janssen Biotech, Inc.

Inventor： Michael Naso ,  T.Shantha Raju ,  Bernard Scallon

IPC: C07K16/24

CPC classification number: C12N9/2402 ,  C07K16/00 ,  C07K16/241 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C12N15/85 ,  C12P21/005 ,  C12Y302/01018

Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.

Abstract translation: 通过用编码唾液酸酶的载体序列转染表达含Fc的蛋白质的细胞系，通过改变Fc区中寡糖的唾液酸化来控制含Fc的蛋白质，例如抗体的性质。 经修饰的含Fc蛋白质具有治疗效用，其中希望控制对FcγRα，FcγRIIA和FcγRIIIA受体的一种或多种的亲和力，ADCC活性，巨噬细胞或单核细胞活化，血清半衰期和 亲和力